Print
Email
Print Edition Stories
MHT's Jackie Noblett: Maine becoming a hub for pet-oriented biotechs
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Funding drugs for rare diseases
Biopharmaceutical firm Excelimmune Inc. has taken in $4.5 million of a planned $8.9 million equity financing, according to a regulatory filing posted with the U.S. Securities and Exchange Commission Friday.
The Woburn-based company develops therapies using human recombinant polyclonal antibodies (HRPA). Its Staphguard drug candidate, used to treat methicillin-resistant Staphylococcus aureus (MRSA), has gone through preclinical studies on mice and awaits an investigational new drug filing.
Excelimmune CEO Quinton Zondervan could not be reached this morning to comment.
Excelimmune was founded in Cambridge in 2006 by Zondervan and chief scientific officer Vincent Coljee. The company landed $1 million in a Series B funding round in February. Its Series A round attracted $2 million in 2007 from Greenheart LLC. In between rounds, Excelimmune also won a Small Business Innovation Research grant from the National Institutes of Health to develop a treatment for Clostridium difficile infection, which can cause diarrhea and intestinal issues.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
